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Durham, North Carolina; Seattle, Washington; and Houston, TexasObjectives This study sought to determine if there is an association between bleed location and
clinical outcomes in acute coronary syndromes (ACS) patients.
Background The prognostic signiﬁcance of bleeding location among ACS patients undergoing
cardiac catheterization is not well known.
Methods We analyzed in-hospital bleeding events among 9,978 patients randomized in the SYNERGY
(Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa
Inhibitors) study. Bleeding events were categorized by location as access site, systemic, surgical, or
superﬁcial, and severity was graded using the GUSTO (Global Use of Strategies to Open Occluded
Coronary Arteries) deﬁnition. We assessed the association of each bleeding location and severity with
6-month risk of death or myocardial infarction using a multicovariate-adjusted Cox proportional
hazard model.
Results A total of 4,900 bleeding events were identiﬁed among 3,694 ACS patients with in-hospital
bleeding. Among 4,679 GUSTO mild/moderate bleeding events, only surgical and systemic bleeds
were associated with an increased risk of 6-month death or myocardial infarction (adjusted hazard
ratio [HR]: 2.52 [95% conﬁdence interval (CI): 2.16 to 2.94, and 1.40 [95% CI: 1.16 to 1.69], respectively).
Mild/moderate superﬁcial and access-site bleeds were not associated with downstream risk (adjusted
HR: 1.17 [95% CI: 0.97 to 1.40], and 0.96 [95% CI: 0.82 to 1.12], respectively). Among 221 GUSTO severe
bleeds, surgical bleeds were associated with the highest risk (HR: 5.27 [95% CI: 3.80 to 7.29]), followed
by systemic (HR: 4.48 [95% CI: 2.98 to 6.72]), and ﬁnally access-site bleeds (HR: 3.57 [95% CI: 2.35
to 5.40]).
Conclusions Among ACS patients who develop in-hospital bleeding, systemic and surgical bleeding
are associated with the highest risks of adverse outcomes regardless of bleeding severity. Although the
most frequent among bleeds, GUSTO mild/moderate access-site bleeding is not associated with
increased risk. These data underscore the importance of strategies to minimize overall bleeding risk
beyond vascular access site management. (J Am Coll Cardiol Intv 2013;6:709–17) ª 2013 by the
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710Among patients with acute coronary syndromes (ACS), the
development of bleeding complications is associated with
poor long-term clinical outcomes and an increased risk of
both ischemic events and death (1–4). Increasingly severe
bleeds are associated with worse clinical outcomes in a step-
wise fashion (5); however, there are limited data examining
the association of bleed location with clinical outcomes.
Recent research has focused on the development of drugs
and techniques that minimize bleeding risk among ACS
patients, particularly among those at risk for access-site
bleeding after percutaneous coronary procedures (6–8).
Nevertheless, the prognostic signiﬁcance of access-site
bleeding, as compared with other types of bleeding such as
systemic organ-related bleeding, surgical bleeding, or
superﬁcial bleeding, is not fully understood, but several
studies have suggested that bleeding location may play an
important role. An analysis from the ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy)sanoﬁ-aventis, Schering-Plough, and
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Abbreviations
and Acronyms
ACS = acute coronary
syndromes
CABG = coronary artery
bypass graft
CI = conﬁdence interval(s)
GP = glycoprotein
HR = hazard ratio(s)
IQR = interquartile range
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TIMI = Thrombolysis In
Myocardial Infarction(6), REPLACE-2 (Randomized
Evaluation in PCI Linking An-
giomax to Reduced Clinical
Events) (9), and HORIZONS-
AMI (Harmonizing Outcomes
with Revascularization and
Stents in Acute Myocardial In-
farction) (7) trials’ combined
dataset demonstrated that the
risk of 1-yearmortality associated
with non-access-site bleeding
was twice that of the 1-year
mortality associated with access-
site bleeding; however, this study
did not account for bleeding
severity (10). Other studies have
provided conﬂicting data
regarding the importance ofaccess-site bleeding, with some demonstrating no associa-
tion with long-term adverse outcomes such as mortality, and
others showing a signiﬁcantly increased risk of death (11,12).
To better understand the prognostic signiﬁcance of
bleeding location and its interaction with severity, we used
data from the SYNERGY (Superior Yield of the New
Strategy of Enoxaparin, Revascularization, and Glycoprotein
IIb/IIIa Inhibitors) trial (13) to accomplish the following
objectives: 1) to characterize the incidence of bleeding inThe Medicines Company. Dr. Wang has re-
ch funding from AstraZeneca, Bristol-Myers
Technologies, Inc., Lilly, sanoﬁ-aventis, Scher-
pany and consulting fees from the American
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3; revised manuscript received March 1, 2013,each location among patients with ACS undergoing a plan-
ned early invasive treatment strategy; 2) to assess the patient
characteristics associated with the location of each hemor-
rhage; and 3) to evaluate the risk-adjusted relationship
between bleeding location and downstream risk of death or
myocardial infarction (MI).
Methods
Study population. The rationale, enrollment criteria, design,
and endpoints of the SYNERGY trial have been previously
described (14). SYNERGY was a prospective, randomized,
open-label, multicenter, international trial designed to
evaluate the efﬁcacy and safety of enoxaparin versus unfrac-
tionated heparin in high-risk patients presenting with non–
ST-segment elevation ACS, who were intended for an early
invasive management strategy. Brieﬂy, the 10,027 patients
enrolled in this study had ischemic symptoms lasting 10
min within 24 h of presentation and at least 2 of the following
high-risk characteristics: age60 years; troponin or creatinine
kinase elevation above the upper limit of normal; or ST-
segment changes on their electrocardiogram. All patients were
to receive aspirin and/or clopidogrel. Glycoprotein (GP) IIb/
IIIa inhibitor use was encouraged. Patients were randomized
to receive unfractionated heparin or enoxaparin, dosed using
weight-adjusted nomograms per study protocol. For patients
undergoing percutaneous coronary intervention (PCI) and
randomized to unfractionated heparin, intravenous unfractio-
nated heparin was given to achieve an activated clotting time of
250 s or lower if GP IIb/IIIa inhibitors were used, whereas
those randomized to enoxaparin received an additional intra-
venous dose of 0.30 mg/kg if the last dose of subcutaneous
enoxaparin was at least 8 h prior to PCI. Among all enrolled
subjects, 49 were inappropriately randomized (13), and
subsequent bleeding data were not collected. This yielded
a ﬁnal study population of 9,978 patients with non–ST-
segment elevation ACS for our analysis.
Deﬁnitions. In this post hoc analysis, in-hospital bleeding
events occurring in patients enrolled in the SYNERGY trial
were stratiﬁed for the purposes of this study by location into 1
of 4 categories: 1) access site; 2) surgical; 3) superﬁcial; or 4)
systemic. Access-site bleeding included any retroperitoneal,
groin, hematoma, or vascular access-site bleeding. Surgical
bleeding included any coronary artery bypass graft (CABG)-
related bleeding or non-CABG-related surgical bleeding.
Superﬁcial bleeding included any bleeding recorded as
epistaxis, ecchymosis, subconjunctival, oropharyngeal, or
superﬁcial injury. Finally, systemic bleeding included all other
“internal” bleeding that was recorded as gastrointestinal,
genitourinary, hemoptysis, intracranial, intraocular, tampo-
nade, hemoglobin drop3 g/dlwithout overt source, or other.
Bleeding episodes were then further graded as severe or
mild/moderate based on the GUSTO (Global Use of
Strategies to Open Occluded Coronary Arteries) deﬁnition
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711(15). We selected the GUSTO criteria to classify bleeding
severity as previous work showed greater correlation between
GUSTO severity with subsequent risk of death/MI
compared with the TIMI (Thrombolysis In Myocardial
Infarction) deﬁnition (15–17). We grouped GUSTO mild
and moderate bleeds for clarity of presentation, as long-term
outcomes for patients with mild or moderate bleeding
appear to be distinct from those of patients with GUSTO
severe bleeding (18).
The current study also sought to deﬁne the relationship
between a clinical bleeding risk prediction score and the
risk of bleeding in different locations. We selected the
CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early
Implementation of the American College of Cardiology/
American Heart Association Guidelines) bleeding risk
score, which classiﬁes patients into very low estimated risk
(score 20), low risk (score 21 to 30), moderate risk (score
31 to 40), high risk (score 41 to 50), or very high risk (score
>50) for bleeding based on presenting characteristics (19).
Six-month death or MI events were adjudicated by an
independent clinical events committee. The deﬁnition forMI
in the SYNERGY trial required a creatine kinase-myocardial
band elevation of 2 the upper limit of normal (14).
Statistical analysis. We compared baseline demographics,
medical history, and in-hospital treatments among groups
deﬁned by the bleeding location categories given herein. To
assess the utility of a commonly applied bleeding risk score
in predicting bleed risk in a speciﬁc location based on pre-
senting patient characteristics, we plotted Kaplan-Meier
estimates of bleeding risk at 14 days (the 90th percentile of
hospital stay) for each bleed location on the y-axis against
categorized CRUSADE bleeding risk scores (20, 21 to 30,
31 to 40, 41 to 50, and >50) on the x-axis (19). For each
bleed location, linear contrasts were used to test whether
there was signiﬁcant evidence of a linear trend between the
CRUSADE score and bleeding risk.
To assess the association of bleeding location and
severity with 6-month risk of death or MI, we ﬁtted
a multivariable adjusted Cox proportional hazard regres-
sion model with time-dependent indicator variables for
each bleeding location and severity level. For each patient,
the relevant bleeding indicator was switched from 0 to 1 at
the ﬁrst time a bleed occurred at a speciﬁc location and
severity level. Bleeding events only counted if they
occurred prior to death or prior to the ﬁrst MI event.
Other covariates entered into the regression model were
adapted from a previously developed and validated risk
model for death or MI in the SYNERGY dataset and
included age, sex, race, height, geographic location,
history of diabetes, tobacco use, prior MI, creatinine, heart
rate on admission, randomization to enoxaparin
(vs. unfractionated heparin), and the composite of age
60 years, ST-segment depression of admissionelectrocardiogram, and positive cardiac biomarkers (20).
For the primary analysis, an individual patient could have
multiple bleeds during follow-up and the analysis assumed
that the effect of a bleed of a particular severity and
location was constant regardless of whether the patient
had only this bleed type or additional types of bleeding.
The resulting hazard ratio for each bleed indicator quan-
tiﬁes the increased risk associated with a particular bleed
location and severity compared with an absence of that
type of bleed. Linear contrasts were used to examine
hypotheses related to the interaction between severity and
location, the average effects of bleeding severity and
bleeding location, and the effects of speciﬁc bleeding
locations independent of severity.
Several patient-level sensitivity analyses were conducted
to evaluate the potential bias introduced by patients with
multiple bleeds of different types. If multiple bleeds were
recorded for a patient, the ﬁrst sensitivity analysis cate-
gorized patients based on the ﬁrst bleeding event at the
highest level of severity experienced; the second sensitivity
analysis categorized patients based on a randomly selected
(not necessarily the ﬁrst) bleeding event at the highest
severity level experienced; and the third sensitivity analysis
counted the ﬁrst bleed per patient regardless of severity.
In these sensitivity analyses, only a single bleed is recog-
nized for each patient during follow-up; therefore, the
reference group for the hazard ratios (HR) is the “no
bleed” group.
Results
Distribution of bleeding. Among 9,978 non–ST-segment
elevation ACS patients in SYNERGY, 3,694 patients (37%)
had at least 1 bleeding event for a total of 4,900 bleeding
events. Access-site bleeding occurred most frequently among
all of the bleeds (1,830 [37%]), followed by surgical (1,214
[25%]), then superﬁcial (1,023 [21%]), and ﬁnally, systemic
bleeding (833 [17%]).
Figure 1 displays the distribution of bleeding events by
GUSTO severity and location. Among all 4,900 bleeding
events, 221 were deemed to be GUSTO severe and 4,679
were GUSTO mild/moderate. Among the 221 GUSTO
severe bleeds, surgical bleeding was the most common, all of
which were CABG-related bleeds, followed by access-site
bleeding, which represented groin bleeding, hematoma, or
retroperitoneal bleeding. Of the 4,679 mild/moderate
GUSTO bleeds, access-site bleeding was the most common,
with groin bleeding or hematoma accounting for the
majority of these bleeds. Surgical bleeding was the next most
frequent type of mild/moderate GUSTO bleeding, followed
by superﬁcial bleeding, and systemic bleeding.
Patient characteristics. Table 1 shows the patient and
treatment characteristics associated with each location of
a bleeding event. Patients with systemic bleeding were more
Figure 1. Distribution of Bleeding Events in SYNERGY by GUSTO Severity and Location
Figure displays counts of bleeding events by location and severity. Patients may have >1 bleeding event. Only bleeding events occurring prior to the death or
myocardial infarction outcome are included. CABG¼ coronary artery bypass graft; GI ¼ gastrointestinal; GUSTO ¼ Global Use of Strategies To Open Occluded Coronary
Arteries; SYNERGY ¼ Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors.
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712likely to be older, have hypertension, diabetes, heart failure,
peripheral arterial disease, or worse renal function. The
CRUSADE predicted bleeding risk score was lowest in the
group that did not bleed [median: 26 (interquartile range
[IQR] 18 to 36)] and highest in the group with systemic
bleeding (median: 36 [IQR: 25 to 46]). A direct relationship
was observed between CRUSADE score–predicted bleeding
risk and the incidence of systemic bleeding, and to a lesser
degree with superﬁcial bleeding (p < 0.0001 for both trends)
(Fig. 2). The CRUSADE bleeding risk score did not predict
the incidence of access-site bleeding or surgical bleeding
(p ¼ 0.49 for both trends).
In-hospital medication use was similar between groups
except for lower rates of clopidogrel andGP IIb/IIIa inhibitor
use among patientswith surgical bleeds, presumably due to the
anticipated surgery (Table 1). Among CABG patients, 45%
were treated with GP IIb/IIIa inhibitors, and 40% received
pre-operative thienopyridine. Femoral access for cardiac
catheterization was used in over 90% of patients in all bleeding
groups, with similar sheath sizes (6-F) and rate of vascular
closure device use. Among patients who experienced surgical
bleeding, 95.4% had CABG. The use of red blood
cell transfusion was highest in those with surgical bleeding
(76.2%), followed by those with systemic bleeding (45.6%); it
was lower among patients with access-site bleeding (19.2%),
superﬁcial bleeding (18.6%), or no bleeding (4.2%).
Location of bleeding and 6-month risk of death or MI. There
were signiﬁcant differences in 6-month risk of death/MI
according to bleed location (p < 0.0001), as well as signif-
icant differences in risk between mild/moderate and severe
bleeds (p < 0.0001). There was no signiﬁcant interaction
between bleeding location and severity (p ¼ 0.204), thusbleed location is an important predictor of 6-month death/
MI, independent of bleeding severity.
Figure 3 shows the multivariable adjusted risks of
6-month death or MI associated with each bleeding loca-
tion and severity. Each location and severity of bleeding
is variably associated with subsequent adverse outcomes
after adjustment for differences in baseline patient charac-
teristics. Among mild/moderate bleeding events, access-site
and superﬁcial bleeds were not signiﬁcantly associated with
downstream risk (adjusted HR: 0.96 [95% conﬁdence
interval (CI): 0.82 to 1.12] and 1.17 (95% CI: 0.97 to 1.40),
respectively). Mild/moderate systemic bleeds and surgical
bleeds were associated with an increased risk of 6-month
death or MI (adjusted HR: 1.40 [95% CI: 1.16 to 1.69] and
2.52 [95% CI: 2.16 to 2.94], respectively).
Regardless of bleed location, GUSTO severe bleeding was
associated with an increased 6-month risk of death or MI
(Fig. 3). Among the patients who experienced GUSTO
severe bleeding, surgical bleeding was associated with the
worst prognosis (HR: 5.27 [95% CI: 3.80 to 7.29]), followed
by systemic bleeding (HR: 4.48 [95% CI: 2.98 to 6.72]), and
ﬁnally, access-site bleeding (HR: 3.57 [95% CI: 2.35 to
5.40]). We were not able to reliably estimate outcomes
associated with the 3 patients who had superﬁcial bleeding
that met GUSTO criteria for severe bleeding.
Sensitivity analyses. Because multiple bleeding events in
a particular patient may have a differential relationship with
outcomes, we performed several sensitivity analyses to
examine patient-level bleeding. In the ﬁrst sensitivity anal-
ysis, if multiple bleeding events were recorded for a patient,
the patient was categorized based on the ﬁrst most severe
bleed. Estimates of 6-month death/MI risk were modestly
Table 1. Patient Characteristics and Treatment Patterns Associated With Each Bleed Location*
Baseline Characteristics
No Bleeding
(n ¼ 6,284)
Access-Site Bleeding
(n ¼ 1,658)
Superﬁcial Bleeding
(n ¼ 873)
Systemic Bleeding
(n ¼ 756)
Surgical Bleeding
(n ¼ 1,181)
Demographics
Age, yrs 67 (60–74) 69 (62–75) 69 (63–76) 73 (65.5–78) 68 (61–74)
Female 2,055 (32.7) 637 (38.4) 362 (41.5) 297 (39.29) 338 (28.6)
Non-white race 913 (14.5) 221 (13.3) 104 (11.9) 116 (15.3) 177 (15.0)
Medical history
HTN 4,196 (66.8) 1,160 (70.0) 616 (70.6) 569 (75.3) 836 (70.8)
DM 1,788 (28.5) 453 (27.3) 257 (29.4) 293 (38.8) 396 (33.5)
Prior MI 1,825 (29.1) 405 (24.5) 249 (28.6) 224 (29.7) 281 (23.9)
Prior CABG 1,130 (18.0) 246 (14.8) 170 (19.5) 146 (19.3) 81 (6.9)
Prior PCI 1,346 (21.4) 292 (17.6) 158 (18.1) 170 (22.5) 182 (15.4)
Prior CHF 551 (8.8) 143 (8.6) 89 (10.2) 119 (15.7) 118 (10.0)
Prior Stroke 304 (4.8) 71 (4.3) 41 (4.7) 60 (7.9) 63 (5.3)
History of PVD 579 (9.2) 156 (9.4) 109 (12.5) 118 (15.6) 122 (10.3)
Features on presentation
Body mass index, kg/m2 27.7 (24.9–31.2) 27.6 (24.7–30.9) 27.7 (24.9–31.3) 27.3 (24.6–31.0) 27.3 (25.0–31.0)
Killip Class
I 5,371 (88.8) 1,405 (88.1) 730 (85.6) 559 (76.8) 962 (84.1)
II 536 (8.9) 153 (9.6) 106 (12.4) 136 (18.7) 146 (12.8)
III 121 (2.0) 27 (1.7) 15 (1.8) 28 (3.9) 26 (2.3)
IV 24 (0.4) 10 (0.6) 2 (0.2) 5 (0.7) 10 (0.9)
Creatinine clearance, y mg/dl 76.7 (58.2–99.5) 71.8 (54.5–94.3) 70.8 (53.5–91.6) 62.2 (46.0–80.2) 75.8 (55.9–97.1)
Baseline hematocrit, % 41.2 (38.1–44.0) 40.7 (37.7–43.8) 40.1 (37.0–43.6) 39.0 (35.0–43.0) 41.0 (37.9–44.1)
CRUSADE bleeding risk score 26 (18–36) 28 (18–38) 29 (20–39) 36 (25–46) 28 (18–37)
In-hospital medications
Aspirin 5,934 (94.4) 1,605 (96.8) 839 (96.1) 724 (95.8) 1,121 (94.9)
Clopidogrel 3,973 (63.2) 1,227 (74.0) 662 (75.8) 479 (63.4) 461 (39.0)
UFH 3,270 (52.0) 717 (43.24) 399 (45.7) 350 (46.3) 572 (48.4)
Enoxaparin 3,014 (48.0) 941 (56.8) 474 (54.3) 406 (53.7) 609 (51.6)
GP IIb/IIIa inhibitor 3,446 (54.9) 1,149 (69.3) 616 (70.6) 482 (63.8) 531 (45.0)
Procedural characteristics
Femoral access 5,566 (95.2) 1,545 (94.2) 738 (90.4) 638 (93.3) 1,132 (97.0)
Sheath size, F 6 (6–6) 6 (6–6) 6 (6–6) 6 (6–6) 6 (6–6)
Vascular closure device used 1,868 (32.8) 580 (36.0) 287 (35.8) 242 (36.0) 330 (29.0)
In-hospital PCI 3,174 (50.5) 999 (60.3) 443 (50.7) 321 (42.5) 50 (4.2)
In-hospital CABG 484 (7.7) 250 (15.08) 149 (17.07) 190 (25.1) 1,127 (95.4)
Hours from catheterization to CABG 64.5 (23.6–140.9) 114.2 (47.5–187.3) 118.9 (45.2–237.2) 90.9 (39.6–185.9) 49.6 (22.8–115.4)
RBC transfusion 265 (4.2) 319 (19.2) 162 (18.6) 345 (45.6) 900 (76.2)
Values are median (interquartile range) or n (%). *CRUSADE bleeding risk score calculated based on the following variables: baseline hematocrit; creatinine clearance; heart rate; systolic blood pressure;
female sex; heart failure on presentation; vascular disease; and diabetes mellitus (19). In the event of bleeding episodes at multiple locations for a single patient, the same patient will contribute
information once to each location grouping in which a bleeding episode was recorded. Only events occurring prior to the death or MI outcome are included. yClearance calculated using Crockoft-Gault
formula.
CABG¼ coronary artery bypass graft; CHF ¼ congestive heart failure; CRUSADE ¼ Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the
American College of Cardiology/American Heart Association Guidelines; DM ¼ diabetes mellitus; GP IIb/IIIa ¼ glycoprotein IIb/IIIa; HTN ¼ hypertension; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention; PVD ¼ peripheral vascular disease; RBC ¼ red blood cell; UFH ¼ unfractionated heparin.
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713higher than those of the primary (bleed-level) analysis, but
the ranking of hazard across bleeding locations was the same
(Table 2). Similar HR and identical ranking were observed
in the second and third sensitivity analyses in which patients
were categorized by a randomly selected (not necessarily the
ﬁrst) bleeding event at the highest level of severity experi-
enced, or by the ﬁrst bleed regardless of severity, respectively.
Overall, the sensitivity analyses demonstrate consistency
with the primary analysis results and support our conclusionsthat bleeding location is variably associated with long-term
adverse outcomes above that predicted by bleeding severity.
Discussion
This study demonstrates that bleeding location provides
additional prognostic information to bleeding severity.
Among bleeding events that occurred during the course of
ACS management, surgical and systemic bleeding are
Figure 2. Risk of Bleeding in Each Location Stratiﬁed by CRUSADE
Bleeding Prediction Score
Kaplan-Meier estimates of bleeding risk at 14 days (90th percentile of length
of stay) in each bleeding location, stratiﬁed by CRUSADE (Can Rapid Risk
Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes with
Early Implementation of the American College of Cardiology/American Heart
Association Guidelines) score category.
Vavalle et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3
Prognostic Signiﬁcance J U L Y 2 0 1 3 : 7 0 9 – 1 7
714associatedwith the highest risks of 6-month adverse outcomes
regardless of severity. Access-site bleeding, although the most
frequent among bleeding events, is associated with the lowestFigure 3. Hazard Ratio for the Risk of 6-Month Death or MI Associated with
Bleeding Severity and Location
Covariates for 6-month death/myocardial infarction (MI) were adapted from
a previously developed and validated risk model for 6-month death or MI in
the SYNERGY dataset and included age, sex, race, height, geographic location,
history of diabetes, tobacco use, prior MI, creatinine, heart rate on admission,
Killip class, randomization to enoxaparin (vs. unfractionated heparin), and the
composite of age 60 years, ST-segment depression of admission electro-
cardiogram, and positive cardiac biomarkers. In this bleed-level analysis, each
hazard ratio (HR) quantiﬁes the increased risk associated with a particular
bleed location and severity compared with an absence of that type of bleed.
CI ¼ conﬁdence interval(s); other abbreviations as in Figure 1.risk of 6-month death or MI among the types of bleeding
studied in this analysis. In fact, the majority of access-site
bleeding was GUSTOmild/moderate in severity and was not
associated with an increased risk of subsequent adverse
outcomes. In contrast, access-site bleeds that met the criteria
forGUSTO severe bleedingwere signiﬁcantly associatedwith
increased risk.
There are several plausible explanations for the association
of systemic and surgical bleeding with worse outcomes. A
larger proportion of patients with these 2 bleeding locations
met criteria for GUSTO severe bleeding. Although
increasing bleeding severity has been associated with worse
clinical outcomes (5), the nonsigniﬁcant interaction we
observed between bleeding location and severity suggests
that bleed location carries incremental and independent
prognostic signiﬁcance. Systemic bleeding events were more
likely to occur in older patients or those with heart failure
and worse renal function on presentation. Although we
cannot fully account for unmeasured confounders, the
association between systemic bleeding with worse outcomes
persisted after adjustment for the comorbid conditions that
were included in the model. Transfusion rates were also
highest in the surgical and systemic bleeding groups. Red
blood cell transfusions have been independently associated
with worse outcomes and may contribute to the association
of these bleeding locations with worse outcomes (21).
Surgical bleeding events were almost uniformly related
to CABG. Certainly, the excess risk of surgical bleeding
may be confounded by the inherent risk associated with
CABG surgery, or it may be a marker of disease severity
mandating surgery. However, several studies directly
comparing CABG and PCI revascularization strategies
show similar (or even improved) downstream risk with
CABG (22–24). Furthermore, the prevalence of mortality
or MI risk factors other than diabetes was not signiﬁcantly
higher in the surgical population. The results of this study
suggest that bleeding complicating the CABG procedur-
edespecially if severedis more than just a bystander in its
associations with downstream risk. Therefore, attempts to
minimize surgical bleeding are paramount to reducing long-
term complications. In fact, this study would suggest that
these bleeds are among the most important bleed types to
prevent.
The ﬁnding that access-site bleeding is associated with
a lower risk of long-term adverse outcomes compared with
other bleeding locations is consistent with the results of
other studies. An analysis of the MULTISTRATEGY
(Multicentre Evaluation of Single High-Dose Bolus Tir-
oﬁban Versus Abciximab With Sirolimus Eluting Stent or
Bare Metal Stent in Acute Myocardial Infarction Study)
found that access-site bleeding was not associated with
the occurrence of death or MI out to 12 months, but that
non-access-site bleeding was highly associated with worse
12-month outcomes after multivariable adjustment (25).
Table 2. Association of Each Bleeding Location and Severity With 6-Month Risk of Death or MI
Severity/Location Combination
“Bleed-Level” Analysis
Sensitivity “Patient-Level” Analyses*
First Most Severe Bleed Random Most Severe First Bleed
HR 95% CI Rank HR 95% CI Rank HR 95% CI Rank HR 95% CI Rank
Severe, surgical 5.27 3.80–7.29 1 6.31 4.56–8.72 1 6.23 4.47–8.69 1 6.01 4.17–8.68 1
Severe, systemic 4.48 2.98–6.72 2 4.83 3.15–7.40 2 5.52 3.66–8.31 2 3.70 2.21–6.18 2
Severe, access site 3.57 2.35–5.40 3 3.88 2.56–5.89 3 3.98 2.62–6.03 3 2.97 1.78–4.95 3
Mild/moderate, surgical 2.52 2.16–2.94 4 2.58 2.18–3.06 4 2.82 2.39–3.32 4 2.58 2.18–3.06 4
Mild/moderate, systemic 1.40 1.16–1.69 5 1.70 1.37–2.12 5 1.69 1.35–2.11 5 1.74 1.40–2.16 5
Mild/moderate, superﬁcial 1.17 0.97–1.40 6 1.32 1.06–1.63 6 1.41 1.13–1.76 6 1.41 1.15–1.73 6
Mild/moderate, access site 0.96 0.82–1.12 7 1.08 0.91–1.28 7 1.13 0.95–1.34 7 1.11 0.94–1.31 7
*Sensitivity analyses conducted on the patient level. For patients with multiple bleeding events, the “ﬁrst severe” bleed categorizes each patient by the ﬁrst GUSTO severe bleed reported, but when no
severe bleeding is reported, the patient is categorized by the ﬁrst GUSTO mild/moderate bleed. “First bleed” categorizes each patient by the ﬁrst reported bleeding event regardless of severity.
CI ¼ conﬁdence interval; GUSTO ¼ Global Use of Strategies To Open Occluded Coronary Arteries; HR ¼ hazard ratio; MI ¼ myocardial infarction.
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715We observed similar rates (31%) of access-site bleeding
compared with the RIVAL (Radial Versus Femoral Access
for Coronary Interventions) study (32%) (8). This study
demonstrated that, compared with transfemoral access,
transradial access for cardiac catheterization can lower rates
of access-site bleeding and ACUITY-deﬁned major bleeding
among ACS patients; however, no difference in the down-
stream outcome of death, MI, or stroke was observed in that
trial. Our study suggests that, though common, access-site
bleeding is prognostically important only when the bleeding
severity is high. Therefore, strategies that only address
access-site bleeding would not be expected to completely
mitigate the risk associated with bleeding complications.
In contrast, optimizing pharmacologic therapies to
prevent systemic and surgical bleeding may be a more
fruitful strategy for improving long-term patient outcomes.
Since the SYNERGY study, bivalirudin use has grown to
approximately 20% among non–ST-segment elevation ACS
patients, whereas GP IIb/IIIa inhibitors are used in
approximately 30% of non–ST-segment elevation ACS
patients (26). A recent analysis of trends in PCI-related
bleeding from the CathPCI Registry has demonstrated an
approximate 20% reduction in post-PCI bleeding for
unstable angina/non–ST-segment elevation MI or elective
PCI between 2005 and 2009, attributed mostly to these
temporal changes in antithrombotic strategies (26).
Risk stratiﬁcation is a key step to the selection of bleed-
ing avoidance strategies, particularly in a cost-conscious
environment. Our study shows that a higher CRUSADE
bleeding risk score is associated with higher rates of systemic
bleeding; therefore, patients with higher CRUSADE bleed-
ing risk scoresmay ideally be targeted for therapieswith amore
favorable bleeding risk proﬁle, such as bivalirudin, which has
been shown to reduce both access and non-access-site
bleeding compared with heparin and GP IIb/IIIa inhibitors
(1). Patients with a history of gastrointestinal bleeding (a
common form of systemic bleeding) or at higher predictedbleeding risk may be candidates for proton pump inhibitor
therapy, which has demonstrated safety in its coadministra-
tion with clopidogrel and efﬁcacy in reducing gastrointestinal
bleeding among patients with coronary artery disease (27).
Further investigation is needed to better understand, deﬁne,
and prevent surgical bleeding. Whereas early use of anti-
platelet and antithrombin therapy is key to optimizing
outcomes (28,29), bypass surgery often cannot be delayed
until full drug washout has occurred and the increased risk of
perioperative bleeding has subsided. Novel therapeutics under
development, with features such as short half-lives or anti-
dotes, are desirable to mitigate bleeding risk among patients
who ultimately require surgery.
Study limitations. As a retrospective analysis examining
complications of treatment, we cannot adjust for unmea-
sured confounders when comparing outcomes between
groups, and causal implications cannot be drawn. We
grouped bleeding events into 4 location categories to permit
adequately powered comparisons of outcomes based on
clinical intuition that bleeds within each location category
are associated with similar prognoses. The difference in
associated outcomes between individual bleed locations
within each group (e.g., genitourinary vs. gastrointestinal) is
unknown. In patients with multiple types of bleeding, the
analysis assumed that the effect of a bleed of a particular
severity and location was constant regardless of whether the
patient only had this type of bleed type, or had additional
types of bleeding, as well. Similarly, we did not account for
the potential effects of repeated bleeds of the same type for
a particular subject, assuming that a recurring bleed of the
same type did not incur additional risk. Nevertheless, a series
of sensitivity analyses were conducted that showed a simi-
larly associated hazard with each bleeding location and
severity, and an identical ranking of the hazard by location
and severity. Not all of the site-reported bleeding events in
this post hoc analysis were adjudicated, but a sample of
bleeds was validated by a review of the medical records with
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716good correlation. In the SYNERGY study, the use of GP
IIb/IIIa inhibitors was high; therefore, care must be taken to
extrapolate these ﬁndings to patients treated with other
antiplatelet strategies. Finally, only 3 patients were catego-
rized as having superﬁcial bleeding that met the GUSTO
criteria for severe, and we were unable to reliably determine
the clinical signiﬁcance of this type of bleeding, due to the
low number of patients in this category.
Conclusions
The location of bleeding among ACS patients treated with
an early invasive strategy appears to have important prog-
nostic implications for long-term outcomes. Surgical and
systemic bleeding events are associated with the highest risks
of long-term adverse outcomes, regardless of bleeding
severity. In contrast, GUSTO mild/moderate access-site
bleeding (though common) is not associated with signiﬁcant
subsequent risk of death or MI. These data illustrate the
prognostic importance of bleeding location, independent of
severity, and underscore the need for bleeding avoidance
strategies beyond access site management to reduce overall
bleeding risk and subsequent adverse events.
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